Phathom Pharmaceuticals (PHAT)Simplify Asset Management Inc. reduced its stake -200K shares
Simplify Asset Management Inc. reduced its stake in Phathom Pharmaceuticals, per its Q3 2025 13F.
- 322K
- Shares reported · -200K vs prior quarter
- 0.07%
- Disclosed portfolio weight
- $3.79M
- Reported value
- Holdings as of
- Sep 30, 2025
- Filed
- Oct 20, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 5, 2025InsiderOfficer sold ~$5.6K of PHAT shares in the open market
- Oct 2, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective October 6, 2025, Sanjeev Narula was appointed as the Chief Financial and Business Officer of Phathom Pharmaceuticals, Inc. (the “Company”). Mr. Narula will also serve as principal financial officer of the Company, replacing Robert Breedlove, Vice President, Finance, who will continue to serve as principal accounting officer.”
What came next
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Phathom Pharmaceuticals
OQRO holds no insider, Congress, fund or contract record for Phathom Pharmaceuticals dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PHAT page.
How this filing works
Other disclosures at Phathom Pharmaceuticals
- SEC Form 13F-HRMay 15, 2026
- SEC Form 13F-HRFeb 17, 2026
- SEC Form 4Sep 9, 2025
- SEC Form 13F-HRAug 14, 2025
- SEC Form 13F-HRAug 7, 2025
- SEC Form 4Jul 18, 2025
Everything OQRO holds on this company is on its PHAT page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data